JP2021500918A5 - - Google Patents
Info
- Publication number
- JP2021500918A5 JP2021500918A5 JP2020530435A JP2020530435A JP2021500918A5 JP 2021500918 A5 JP2021500918 A5 JP 2021500918A5 JP 2020530435 A JP2020530435 A JP 2020530435A JP 2020530435 A JP2020530435 A JP 2020530435A JP 2021500918 A5 JP2021500918 A5 JP 2021500918A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- cells
- mouse
- immunodeficient
- test substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543218P | 2017-08-09 | 2017-08-09 | |
| US62/543,218 | 2017-08-09 | ||
| US201762554818P | 2017-09-06 | 2017-09-06 | |
| US62/554,818 | 2017-09-06 | ||
| PCT/US2018/046021 WO2019032836A1 (en) | 2017-08-09 | 2018-08-09 | IMMUNODEFICIENT MOUSE EXPRESSING THE HUMAN INTERLEUKINE 15 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500918A JP2021500918A (ja) | 2021-01-14 |
| JP2021500918A5 true JP2021500918A5 (cg-RX-API-DMAC7.html) | 2023-11-13 |
| JP7404237B2 JP7404237B2 (ja) | 2023-12-25 |
Family
ID=63557672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530435A Active JP7404237B2 (ja) | 2017-08-09 | 2018-08-09 | ヒトインターロイキン15を発現する免疫不全マウス |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200236916A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3664603B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7404237B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102693739B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN112118734A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018313892B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3072331A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL272475B2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202001109PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019032836A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018102546A1 (en) | 2016-11-30 | 2018-06-07 | The Jackson Laboratory | Humanized mouse model with improved human innate immune cell development |
| WO2021150936A1 (en) * | 2020-01-22 | 2021-07-29 | City Of Hope | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer |
| WO2021159035A1 (en) | 2020-02-07 | 2021-08-12 | City Of Hope | Oncolytic virus compositions and methods for the treatment of cancer |
| CN111485001A (zh) * | 2020-04-14 | 2020-08-04 | 澎立生物医药技术(上海)有限公司 | 具有nk细胞及adcc能力的人源化免疫系统小鼠的构建方法 |
| CN114304065A (zh) * | 2021-12-31 | 2022-04-12 | 江苏大学 | 一种阻断il-8联合抗pd-1抗体治疗胃癌的动物模型构建及应用 |
| WO2024029561A1 (ja) * | 2022-08-02 | 2024-02-08 | 学校法人東海大学 | 担がん-免疫不全非ヒト動物、これを用いた供試物質に関するがん免疫応答評価方法 |
| AU2023338373A1 (en) * | 2022-09-08 | 2025-04-03 | The Jackson Laboratory | Humanized immunodeficient mouse models |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| JP6492095B2 (ja) * | 2013-10-15 | 2019-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化il−15動物 |
| US20150282460A1 (en) * | 2014-04-04 | 2015-10-08 | Crown Bioscience Inc. (Taicang) | Animal model with human immune system |
| ES2950399T3 (es) * | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
| JP6654001B2 (ja) * | 2015-05-27 | 2020-02-26 | 公益財団法人実験動物中央研究所 | ヒトil−15分泌免疫不全マウス |
| TWI810145B (zh) * | 2015-06-23 | 2023-08-01 | 杰克森實驗室 | 具有病患衍生之異種移植物之非hla配對的人源化nsg小鼠模式 |
-
2018
- 2018-08-09 IL IL272475A patent/IL272475B2/en unknown
- 2018-08-09 KR KR1020207006440A patent/KR102693739B1/ko active Active
- 2018-08-09 CN CN201880063498.2A patent/CN112118734A/zh active Pending
- 2018-08-09 EP EP18769249.6A patent/EP3664603B1/en active Active
- 2018-08-09 CA CA3072331A patent/CA3072331A1/en active Pending
- 2018-08-09 JP JP2020530435A patent/JP7404237B2/ja active Active
- 2018-08-09 SG SG11202001109PA patent/SG11202001109PA/en unknown
- 2018-08-09 US US16/637,621 patent/US20200236916A1/en active Pending
- 2018-08-09 CN CN202310853270.6A patent/CN116998459A/zh active Pending
- 2018-08-09 WO PCT/US2018/046021 patent/WO2019032836A1/en not_active Ceased
- 2018-08-09 AU AU2018313892A patent/AU2018313892B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lawal et al. | The immunology of hepatocellular carcinoma | |
| Chen et al. | IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy | |
| Munir et al. | Classical Hodgkin lymphoma: from past to future—a comprehensive review of pathophysiology and therapeutic advances | |
| Papait et al. | Mesenchymal stromal cells from fetal and maternal placenta possess key similarities and differences: potential implications for their applications in regenerative medicine | |
| Zhang et al. | PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy | |
| Shaver et al. | Natural killer cells: the linchpin for successful cancer immunotherapy | |
| Airoldi et al. | γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes | |
| Tang et al. | Molecular mechanisms of low dose ionizing radiation-induced hormesis, adaptive responses, radioresistance, bystander effects, and genomic instability | |
| Pollyea et al. | Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials | |
| Wang et al. | Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer | |
| Ahmed et al. | CD57+ memory T cells proliferate in vivo | |
| Chen et al. | TIGIT blockade exerts synergistic effects on microwave ablation against cancer | |
| Rao et al. | Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies | |
| Bascuas et al. | Salmonella immunotherapy improves the outcome of CHOP chemotherapy in non-Hodgkin lymphoma-bearing mice | |
| Caldemeyer et al. | Donor lymphocyte infusions used to treat mixed-chimeric and high-risk patient populations in the relapsed and nonrelapsed settings after allogeneic transplantation for hematologic malignancies are associated with high five-year survival if persistent full donor chimerism is obtained or maintained | |
| Bigler et al. | Stress-induced in vivo recruitment of human cytotoxic natural killer cells favors subsets with distinct receptor profiles and associates with increased epinephrine levels | |
| Ali et al. | The role of anti-thymocyte globulin or alemtuzumab-based serotherapy in the prophylaxis and management of graft-versus-host disease | |
| Bernasconi et al. | Immune escape after hematopoietic stem cell transplantation (HSCT): from mechanisms to novel therapies | |
| Lake et al. | Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma | |
| Bachiller et al. | Natural killer cells in immunotherapy: are we nearly there? | |
| Braun et al. | Immunotherapy in myeloproliferative diseases | |
| Kariminia et al. | CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results | |
| Williams et al. | CD16+ NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice | |
| Barough et al. | Gemcitabine‐loaded injectable hydrogel for localized breast cancer immunotherapy | |
| Gramatica et al. | EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes |